Penn Medicine's 2020 Updates in Care of the Hematologic Malignancies Patient
ASH 2019 Update on Novel Therapies for Higher Risk MDS: IDH Inhibitors, Azacitidine Combinations (Ven+Aza & Magrolimab+Aza), Targeting TP53 Mutations
Comments 0
Login to view comments.
Click here to Login
